Menu Search
Equities

Allovir Inc

ALVR:NAQ

Allovir Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.7514
  • Today's Change-0.039 / -4.89%
  • Shares traded3.52k
  • 1 Year change-67.05%
  • Beta0.7749
Data delayed at least 15 minutes, as of Sep 20 2024 15:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Allovir Inc's net income fell 12.87% from a loss of 168.71m to a larger loss of 190.42m despite flat revenues.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-67.85%
Return on equity-80.33%
Return on investment-73.72%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Allovir Inc fell by 15.97m. Cash Flow from Financing totalled 70.50m or -- of revenues. In addition the company used 124.45m for operations while cash from investing totalled 37.99m.
Cash flow per share-1.22
Price/Cash flow per share--
Book value per share1.04
Tangible book value per share1.04
More ▼

Balance sheet in USDView more

Allovir Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio55.08
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.